Updated on 20 December 2012
Quintiles signs bioanalytical deal with Korean CRO BioCore
Singapore: To enhance its bioanalytical service offerings in Asia, Quintiles has signed an exclusive partnership with BioCore, a leading Seoul-based bioanalytical contract research organization (CRO). Under the agreement, BioCore will provide its services to Quintiles exclusively for a two-year period.
"Gathering high-quality bioanalytical data early in development is crucial to biopharma companies for making informed decisions that increase their probability of success in expensive later-stage trials," said Ms Jenny Zhang, vice president and general manager of Asia Laboratories, Quintiles. "This partnership with BioCore is part of our plan to add local capabilities as needed to augment Quintiles' good laboratory practice (GLP) bioanalytics lab and College of American Pathologists (CAP). In this way we put our customers' needs first, and can work locally, regionally or globally as circumstances require."
Quintiles' growing global bioanalytical capabilities began with its acquisition of Advion BioServices in 2011. This group, now called Advion Bioanalytical Labs, a Quintiles company, will continue to serve Quintiles' global markets while BioCore is available as an option for customers who desire a local bioanalytical lab in Asia.
BioCore president and CEO Hyung Sik Choie said, "This partnership expands BioCore's bioanalysis and bioequivalence studies beyond Korea to other Asian countries. Our vision is to become more global; this alliance advances our efforts to achieve that vision."
BioCore is South Korea's largest provider of bioanalytical liquid chromatography-tandem mass spectrometry (LC/MS/MS) services. BioCore was South Korea's first GLP-complaint centralized bioanalytical CRO (2005) and first to be certified by the Korea Food and Drug Administration as a Bioequivalence Testing Institution (2008).